Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
about
AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndromeTargeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidenceTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyConcise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationTargeting bone physiology for the treatment of metastatic prostate cancerTargeting the molecular and cellular interactions of the bone marrow niche in immunologic diseaseTumor stroma as targets for cancer therapyHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyMLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonismDiabetes impairs hematopoietic stem cell mobilization by altering niche function.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.PlerixaforAssociation between mobilization regimen and PFS after auto-SCT for multiple myeloma.An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.Turning CD34 Non-Mobilizers into Mobilizers: A Case Report Involving Plerixafor (AMD3100).Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.SMAD signaling regulates CXCL12 expression in the bone marrow niche, affecting homing and mobilization of hematopoietic progenitorsPlerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsPredicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceSafety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.The intricate role of CXCR4 in cancer.Significant mobilization of both conventional and regulatory T cells with AMD3100.SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation.HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic MalignanciesA phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaSuccessful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment.
P2860
Q24623703-EA0320CB-2276-4615-8860-C44129BD827AQ26770388-E70109D8-4348-43F1-B9B9-2C1178254FC2Q26771159-AB19C432-EC67-414A-8150-A2A53DBA6E4EQ26825518-AA32B0AF-9214-4AC7-8A8C-F099F4D31DDEQ26863249-25E3CC02-B8A7-4E2A-9BF4-8FA609082D72Q26865498-CCCB91F0-7C45-4708-929D-4B2A1DB56860Q27015980-BFC57B17-24ED-4CA0-8E37-5EC4D4F58812Q27021570-03CCDEE2-FF91-4AC0-A80A-B3F19ADA3FFAQ28658170-5541F142-46C5-4606-B466-9325AD905D34Q30543776-90C1DBAA-0C46-4FDE-9D2D-07B3D7F3B566Q33411277-706D2EAA-E243-41EA-9463-8C3540314FECQ33623571-9CF25EA9-AF10-4B0C-9756-540F4F66E443Q33677057-823C0312-CBA6-48CC-BD24-702A969E274FQ33708995-71BCEC31-F786-46C9-8169-76160EF7498BQ33885517-E14B04B9-ABB8-493F-9390-5197CACC1925Q33889676-53CA4037-53A6-4892-ABA2-D8BB3F6A4BBAQ34016950-62B3871A-27B0-456A-8FCA-17B5EC31C11AQ34114055-8B9B52CF-B192-4A45-83A5-AFF10DC3B818Q34207531-579C0A47-8AE3-4427-AD2D-D3CC03AD018CQ34209313-1347F343-2229-4D79-A81B-463C626BDB87Q34263566-6213BBA7-4E60-49DC-95C2-52FB9D0F3817Q34265754-F5EC6E57-786A-45A3-8400-3E8E1AE04C87Q34268121-FADEDE34-7F5E-4DD1-B5EC-C27C186977A8Q34377450-3788F660-8DA8-469B-A26B-B533ED8C5B11Q34432943-D7A20551-1F88-40AC-A560-A733AF2381DDQ34454386-483473E5-5697-46A7-BFF6-A691DC77B993Q34454624-7E430846-B9B3-496A-9E0E-79F0FC5068CFQ34490998-3F1C8132-2621-4717-9F6F-0CAE23E44A52Q34762492-8D116394-9F0A-4A91-878E-0056684476BFQ34971081-22CF3476-61B4-4AEF-B84E-034BF5C4C2AEQ35041174-EE6DBCE7-C9B4-445A-98B1-A2D5A36A47CCQ35067624-C6261C67-596F-4C6A-9A4E-40711E02F91FQ35623657-A8C221EE-53E6-4AEB-89ED-9E6EDD26824FQ35673839-3662A69D-546A-45C3-B405-2551D3AB5997Q35838285-AAE5C7F1-A7DF-4539-ADC4-188E2C6AF2CAQ35858991-55FD2183-557F-4644-A8F3-D0C89A6CEF11Q35911212-07664A87-8B8D-43C3-96AF-46B79C211769Q35949372-864BFFEB-FB06-45CE-B3A6-C8A6D0C6BC13Q35953355-6B786B90-8830-44C3-B768-8306AE5053EFQ35991738-B43D1176-49AF-4603-ABB5-444A4811870A
P2860
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@en
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@nl
type
label
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@en
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@nl
prefLabel
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@en
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@nl
P2093
P1433
P1476
Plerixafor and G-CSF versus pl ...... atients with multiple myeloma.
@en
P2093
3102 Investigators
Auayporn Nademanee
Dennis Cooper
Edward A Stadtmauer
Gary Bridger
Gary Calandra
Ivana N M Micallef
John F DiPersio
Jonathan L Kaufman
Mitchell Horwitz
P304
P356
10.1182/BLOOD-2008-08-174946
P407
P577
2009-04-10T00:00:00Z